INHX Inhibitex, Inc. (MM)

Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced today that Russell H. Plumb, president and chief executive officer of Inhibitex, Inc., is scheduled to present at the following two conferences in November 2008: The Rodman & Renshaw Annual Global Investment Conference on November 11, 2008 at 3:15 p.m. EST at The New York Palace Hotel in New York. The Lazard Capital Markets 5th Annual Healthcare Conference on November 19, 2008 at 2:30 p.m. EST at The St. Regis Hotel in New York. A live audio webcast of each of the presentations will be available under the �News and Events� section of the company�s website at www.inhibitex.com. The webcasts will be archived and available on the Inhibitex website after each of the events for a period of 30 days. About Inhibitex Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases. The Company�s pipeline includes FV-100, its clinical-stage oral nucleoside analogue in development for the treatment of herpes zoster (shingles), as well as a series of pre-clinical stage HCV polymerase inhibitors and HIV integrase inhibitors. Inhibitex has also licensed certain of its proprietary MSCRAMM� protein technology to Wyeth for the development of staphylococcal vaccines and to 3M for the development of diagnostics. For additional information about the Company, please visit www.inhibitex.com. Inhibitex� and MSCRAMM� are registered trademarks of Inhibitex, Inc.